Author

Tanju Nacak

Observed names: Nacak, Tanju, T Nacak

Observed institution: Dr Falk Pharma (Germany)

OpenAlex ID: A5079467454

Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

2018 · Stephan Miehlke, Daniela Aust, et al. · Gastroenterology · 71

Rifamycin SV-MMX® for treatment of travellers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria

2018 · Robert Steffen, Zhi-Dong Jiang, et al. · Journal of Travel Medicine · 40

PDF

Distribution of histopathological features along the colon in microscopic colitis

2020 · Anne-Marie Kanstrup Fiehn, Stephan Miehlke, et al. · International Journal of Colorectal Disease · 30

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis

2023 · Wolfgang Kruis, Silke Meszaros, et al. · United European Gastroenterology Journal · 19

PDF

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial

2017 · Axel Dignass, Robert Schnabel, et al. · United European Gastroenterology Journal · 14

Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double‐blind study

2020 · Wolfgang Kruis, Tomas Poškus, et al. · GastroHep · 7

Efficacy and safety of prolonged release budesonide granules in mesalazine‐refractory ulcerative colitis: A multi‐centre Phase IIa study (TOPICAL‐1)

2020 · Klaus Fellermann, Ingolf Schiefke, et al. · United European Gastroenterology Journal · 6

PDF

P752 Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trial

2018 · S Miehlke, D Aust, et al. · Journal of Crohn s and Colitis · 3

Budesonide is superior to mesalazine and placebo for induction of remission in lymphocytic colitis

2017 · Miehlke, Stephan, Aust, Daniela E., et al. · Lithuanian University of Health Sciences · 1

Naronaprid bei idiopathischer und diabetischer Gastroparese: Ergebnisse einer randomisiert-kontrollierten Phase 2b-Studie

2026 · J Keller, J D Ulrich, et al. · Zeitschrift für Gastroenterologie

505a NARONAPRIDE IN IDIOPATHIC AND DIABETIC GASTROPARESIS: RESULTS FROM A PHASE 2B RANDOMIZED CONTROL TRIAL

2026 · Jan F. Tack, Jörg D. Ulrich, et al. · Gastrointestinal Endoscopy

505a NARONAPRIDE IN IDIOPATHIC AND DIABETIC GASTROPARESIS: RESULTS FROM A PHASE 2B RANDOMIZED CONTROL TRIAL

2026 · Jan F. Tack, Jörg D. Ulrich, et al. · Gastroenterology

Su1852: DISEASE CLEARANCE AFTER ONE YEAR OF MAINTENANCE THERAPY WITH ORAL MESALAMINE IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION: A POST HOC ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL

2025 · Wolfgang Kruis, Tanju Nacak, et al. · Gastroenterology

Su1916 RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH (HIGH DOSE) MESALAMINE IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POSTHOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS

2020 · Wolfgang Kruis, Tanju Nacak, et al. · Gastroenterology

Signifikante Verbesserung der Krankheisaktivität (Microscopic Colitis Disease Activity Index – MCDAI) durch Budesonid bei lymphozytärer Kolitis

2019 · S Miehlke, D Aust, et al. · Zeitschrift für Gastroenterologie

Tu1750 – Novel Rifamycin Sv Multi-Matrix Formulation for Treatment of Acute Uncomplicated Diverticulitis: Results of a Prospective Double-Blind, Placebo-Controlled, Randomized Study

2019 · Wolfgang Kruis, Tomas Poskus, et al. · Gastroenterology

PDF

Tu1741 – A Novel Oral Formulation of Budesonide is Effective for Induction of Remission in Mesalamine Refractory Ulcerative Colitis (TOPICAL-1)

2019 · Klaus Fellermann, Ingolf Schiefke, et al. · Gastroenterology

Sa1760 - Novel Microscopic Colitis Disease Activity Index Reflects High Efficacy of Oral Once Daily Budesonide Treatment in Lymphocytic Colitis: Post-HOC Analysis of a Randomized, Double-Blind, Double-Dummy, Multicenter, Trial

2018 · Stephan Miehlke, Daniela Aust, et al. · Gastroenterology

816 - Oral Once Daily Budesonide Granules Induce Clinical Remission in Lymphocytic Colitis and Improve Quality of Life: A Randomized, Double-Blind, Double-Dummy Multicenter Trial

2018 · Stephan Miehlke, Daniela Aust, et al. · Gastroenterology

Budesonid ist effektiver als Mesalazin oder Plazebo in der Remissionsinduktion der Lymphozytären Kolitis

2017 · S Miehlke, D Aust, et al. · Zeitschrift für Gastroenterologie

A Novel Multi-Matrix Formulation of the Broad-Spectrum, Poorly Absorbed Antibiotic Rifamycin SV is Equally Effective as Systemic Ciprofloxacin in the Oral Treatment of Travelers' Diarrhea: a Double-Blind, Double-Dummy, Multicentre, Randomized Study

2017 · Robert Steffen, Herbert L. DuPont, et al. · Gastroenterology

Works count: 23

Citation count: 191

H-index: 6

I10-index: 5